title: ACS Treatment Continues to Improve: But Price Matters.
abstract: Over 90% of patients achieve adequate levels of platelet inhibition with both Prasugrel and Ticagrelor. The introduction of Prasugrel was met with some hesitation from physicians because of the significant increase in cost. This pharmaceutically sponsored and authored retrospective study suggests that both agents are effective.
authors.affiliation: Chief of Cardiology, St. Luke's Medical Center, Professor of Medicine, University of Arizona College of Medicine - Phoenix. larmore_cynthia_jean@lilly.com.
authors.forename: Richard R
authors.initials: RR
authors.lastname: Heuser
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D000241:Adenosine / Q000627:therapeutic use; D006801:Humans; D062645:Percutaneous Coronary Intervention; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D000068799:Prasugrel Hydrochloride; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D000068799:Prasugrel Hydrochloride; D000241:Adenosine